Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plazomicin's BSI Indication Could Be First LPAD Drug – If Achaogen Can Convince US FDA Of Efficacy

Executive Summary

Advisory committee will review applications for cUTI indication, which looks good, and the BSI indication, which looks fraught.

You may also be interested in...



A Tale Of Two Advisory Panels: The Divergent Fates Of Pretomanid And Plazomicin

The TB Alliance and Achaogen both presented their drugs to US FDA's Antimicrobial Drugs Advisory Committee with small patient populations in pivotal trials. Why did one fare better than the other?

Antibiotic Test Case: Will LPAD + Non-Inferiority = Approval For Plazominicin's BSI Indication?

 US FDA Office of Antimicrobial Products Director Ed Cox explained to an advisory committee why a non-inferiority analysis could work in the context of an unmet need. 

Plazomicin's BSI Indication Gets 'No' From Advisory Panel, But US FDA Still Might Approve Under LPAD Pathway

Achaogen should at least be reassured by advisory committee's unanimous 'yes' vote for plazomicin's cUTI indication. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS123006

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel